Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DWTX

Dogwood Therapeutics Inc

Apr 03 • 04:00PM ET

4.18

Dollar change +0.13
Percentage change 3.21	%

Healthcare • Biotechnology • USA • NASD

Peers: AZN RARE NBIX IRWD XENE ANIP SAGE PRTA ATNM RDHL

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.17	Insider Own	18.63%	Shs Outstand	1.91M	Perf Week	-30.10%
Market Cap	7.99M	Forward P/E	-	EPS next Y	-5.98	Insider Trans	0.00%	Shs Float	1.56M	Perf Month	-6.07%
Income	-12.86M	PEG	-	EPS next Q	-3.70	Inst Own	1.61%	Short Float	12.42%	Perf Quarter	67.87%
Sales	0.00M	P/S	-	EPS this Y	17.73%	Inst Trans	-8.39%	Short Ratio	0.05	Perf Half Y	7.32%
Book/sh	-7.60	P/B	-	EPS next Y	41.94%	ROA	-23.44%	Short Interest	0.19M	Perf Year	-69.04%
Cash/sh	7.77	P/C	0.54	EPS next 5Y	32.44%	ROE	-200.48%	52W Range	1.62 - 29.28	Perf YTD	67.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.88%	ROI	-16.12%	52W High	-85.72%	Beta	2.01
Dividend TTM	-	Quick Ratio	5.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	158.02%	ATR (14)	1.30
Dividend Ex-Date	-	Current Ratio	5.21	EPS Y/Y TTM	-57.84%	Oper. Margin	-	RSI (14)	38.53	Volatility	18.27% 25.98%
Employees	12	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-339.20%	Payout	-	Rel Volume	0.06	Prev Close	4.05
Sales Surprise	-	EPS Surprise	-344.52%	Sales Q/Q	-	Earnings	Mar 14 BMO	Avg Volume	3.62M	Price	4.18
SMA20	-35.60%	SMA50	-46.10%	SMA200	-17.92%	Trades		Volume	201,251	Change	3.21%

Today 09:00AM	Dogwood Therapeutics, Inc. Regains Nasdaq Compliance (GlobeNewswire)
Mar-31-25 03:45PM	Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -11.17%
Mar-18-25 08:45AM	Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain (GlobeNewswire) -6.90%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -20.83%
Mar-13-25 09:00AM	Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -27.76%
08:30AM	Loading…
Mar-12-25 08:30AM	Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward (GlobeNewswire)
Jan-21-25 09:15AM	Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 (GlobeNewswire) +68.45%
Nov-18-24 08:45AM	Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study (GlobeNewswire) -37.71%
Nov-08-24 02:35AM	Q3 2024 Dogwood Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
Nov-07-24 07:05AM	Dogwood Therapeutics Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 09:15AM	Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 (GlobeNewswire)
Oct-30-24 09:15AM	Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.73%
Oct-08-24 08:29AM	Virios Therapeutics Transforms into Dogwood Therapeutics (TipRanks) +12.40%
Oct-07-24 07:05AM	Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: DWTX ) (GlobeNewswire) -18.50%
09:15AM	Loading…
Aug-08-24 09:15AM	Virios Therapeutics Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 09:41AM	Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jul-23-24 09:15AM	Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center (GlobeNewswire) +6.70%
May-22-24 01:30PM	Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) +10.83%
May-20-24 02:19PM	Top Midday Decliners (MT Newswires) -43.94%
10:25AM	Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain? (InvestorPlace)
09:20AM	Why Is Virios Therapeutics (VIRI) Stock Down 44% Today? (InvestorPlace)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
03:54AM	Virios Therapeutics Prices $1.7 Million Common Stock Offering (MT Newswires)
May-19-24 08:53PM	Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire)
May-17-24 04:10PM	Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) -8.96% -43.94%
May-13-24 10:49AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:45AM	Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -13.15%
May-02-24 09:15AM	Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 (GlobeNewswire)
Mar-26-24 09:15AM	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID (GlobeNewswire) -8.45%
09:15AM	Loading…
Feb-29-24 09:15AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 09:15AM	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones (GlobeNewswire)
Jan-22-24 09:00AM	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID (GlobeNewswire) -40.27%
Jan-02-24 07:05AM	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID (GlobeNewswire)
Nov-14-23 09:55AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:05AM	Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -10.54%
Nov-06-23 07:05AM	Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 (GlobeNewswire) +6.40%
Oct-12-23 07:05AM	Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023 (GlobeNewswire)
Sep-18-23 07:05AM	Virios Therapeutics Announces Termination of At-The-Market Sales Agreement (GlobeNewswire)
Sep-12-23 07:05AM	Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023 (GlobeNewswire)
Aug-15-23 07:48AM	VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024 (Zacks)
Aug-14-23 07:05AM	Virios Therapeutics Announces Halt to At-The-Market Offering Sales (GlobeNewswire) +18.52%
Aug-12-23 09:40AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 07:05AM	Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -31.21%
Aug-09-23 07:05AM	Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia (GlobeNewswire) -7.10%
Aug-03-23 04:05PM	Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-24-23 08:40AM	VIRI: Encouraging Results for IMC-2 in Long COVID (Zacks)
Jul-17-23 02:20PM	Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People (Benzinga) -20.25%
07:05AM	Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study (GlobeNewswire)
May-25-23 04:05PM	Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -9.70% +19.01%
May-16-23 10:26AM	VIRI: Ready to Move IMC-1 Into Phase 3 Program (Zacks Small Cap Research)
May-15-23 07:05AM	Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia (GlobeNewswire)
May-11-23 07:49AM	VIRI Stock Earnings: Virios Beats EPS Estimates (InvestorPlace) -6.96%
07:39AM	We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate (Simply Wall St.)
07:05AM	Virios Therapeutics Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 07:05AM	Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +9.75%
Apr-25-23 01:07PM	Virios Therapeutics Shares Almost Double In Trading Session - Here's Why (Benzinga) +55.13%
Apr-24-23 04:15PM	Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia (GlobeNewswire) -8.03%
Mar-16-23 07:10AM	VIRI: Anticipating Update on IMC-1 Following End-of-Phase 2 Meeting with FDA (Zacks Small Cap Research)
Mar-14-23 07:05AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-07-23 07:05AM	Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 (GlobeNewswire) -14.32%
Feb-13-23 07:05AM	Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023 (GlobeNewswire)
Jan-05-23 07:00AM	Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program (GlobeNewswire) +10.93%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 07:05AM	Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase (Business Wire)
Nov-22-22 06:15AM	VIRI: Ready to Approach FDA with Phase 3 Plans (Zacks Small Cap Research)
Nov-14-22 07:05AM	Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) -10.50%
Nov-03-22 07:05AM	Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 (Business Wire)
Sep-23-22 07:27AM	VIRI: Raises Gross Proceeds of $5 Million Through Underwritten Public Offering (Zacks Small Cap Research) -5.93%
Sep-22-22 04:15PM	Virios Therapeutics, Inc. Announces Closing of Public Offering (Business Wire) -5.21%
Sep-19-22 10:04PM	Virios Therapeutics, Inc. Announces Pricing of Public Offering (Business Wire) -77.19% -75.50%
04:05PM	Virios Therapeutics, Inc. Announces Proposed Public Offering (Business Wire)
11:20AM	VIRI: FORTRESS Trial Does Not Meet Primary Efficacy Endpoint (Zacks Small Cap Research)
09:33AM	Virios Therapeutics Shares Tank After Failing Fibromyalgia Study (Benzinga)
08:22AM	Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate (MarketWatch)
07:05AM	Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia (Business Wire)
Sep-16-22 09:30AM	New to The Street TV / Newsmax TV Announces its Eight Interviews on This Week's TV Broadcast, Episode #386, September 18, 2022, 10-11 AM ET (GlobeNewswire) +13.02%
Sep-12-22 09:30AM	New to The Street TV Announces Four Corporate Interviews on its 384th TV Show, Airing on the Fox Business Network, Tonight, Monday, September 12, 2022, at 10:30 PM PT (GlobeNewswire) +7.69%
Sep-05-22 06:47AM	Here's Why Virios Therapeutics (NASDAQ:VIRI) Must Use Its Cash Wisely (Simply Wall St.)
Aug-15-22 07:24AM	VIRI: Topline Results for FORTRESS Trial Expected in September 2022 (Zacks Small Cap Research)
07:05AM	Virios Therapeutics Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial (Business Wire)
Aug-11-22 07:05AM	Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) +8.45%
Aug-10-22 04:01PM	Virios Therapeutics, Inc. to Present at Investor Summit Groups Q3 Virtual Conference (Business Wire)
Aug-08-22 08:30AM	Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans (Newsfile)
Aug-04-22 07:05AM	Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022 (Business Wire)
Jul-26-22 08:30AM	Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment (Newsfile)
Jul-19-22 08:30AM	Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results (Newsfile)
Jun-01-22 07:05AM	Virios Therapeutics Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia (Business Wire)
May-17-22 12:05PM	VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022 (Zacks Small Cap Research) +17.05%
May-12-22 07:05AM	Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) +5.44%
May-05-22 07:05AM	Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (Business Wire) -5.54%
Apr-28-22 07:05AM	Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for Fibromyalgia (Business Wire)
Mar-28-22 07:10PM	We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate (Simply Wall St.) -11.62%
Mar-21-22 06:25AM	VIRI: Testing Combination Antiviral Therapy to Treat Long COVID (Zacks Small Cap Research)
Mar-17-22 07:05AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (Business Wire) +8.01%
Mar-10-22 07:05AM	Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022 (Business Wire)
Mar-08-22 04:05PM	Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022 (Business Wire) +6.60%
Feb-28-22 07:05AM	Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID (Business Wire)
Feb-01-22 03:00AM	A Fireside Chat with Greg Duncan - CEO of Virios Therapeutics (Zacks Small Cap Research)
Jan-26-22 04:30PM	RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28 (ACCESSWIRE)

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DWTX

Dogwood Therapeutics Inc

Upgrade your FINVIZ experience